ClinicalTrials.gg
CompletedNCT05327491Updated Dec 14, 2023Results posted

A Study in Healthy Volunteers to Compare the Pharmacokinetics of Sotorasib Administered as 1 or 2 Tablets

A Phase 1 interventional study of Sotorasib in Healthy Participants, sponsored by Amgen. Completed at 4 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-14.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The primary objective of the study is to compare the pharmacokinetics (PK) of sotorasib administered orally as 1 tablet under fasted conditions to sotorasib administered orally as 2 tablets under fasted conditions.

02

Conditions studied

  • Healthy Participants

Keywords

  • Sotorasib
  • AMG 510
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male participants or female participants, between 18 and 60 years of age (inclusive), at the time of Screening.
  • , between 18 and 30 kg/m\^2 (inclusive), at the time of Screening.
  • Females of nonchildbearing potential.

Exclusion criteria

Exclusion Criteria:

  • Inability to swallow oral medication or history of malabsorption syndrome.
  • History of , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee) and in consultation with the Sponsor.
  • Poor peripheral venous access.
  • History or evidence, at Screening or Check in, of disorder, condition, or disease, including history of myolysis, not otherwise excluded that, in the opinion of the Investigator (or designee), would pose a risk to participants safety or interfere with the study evaluation, procedures, or completion.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
146 participants (actual)

Study arms

  • Experimental
    Treatment Sequence ABC

    Participants will be administered sotorasib orally in the following order: Period 1 - as 1 tablet (test 1) Period 2 - as 2 tablets (reference) Period 3 - as 1 tablet (test 2)

    Drug: Sotorasib

  • Experimental
    Treatment Sequence BAC

    Participants will be administered sotorasib orally in the following order: Period 1 - as 2 tablets (reference) Period 2 - as 1 tablet (test 1) Period 3 - as 1 tablet (test 2)

    Drug: Sotorasib

Interventions

  • Oral Tablet

    Also known as: AMG 510

06

What researchers measure

Primary outcomes

  1. Period 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Sotorasib

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on the 1st day of each period (Days 1 and 4)

  2. Period 1 and 2: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Sotorasib

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on the 1st day of each period (Days 1 and 4)

  3. Period 1 and 2: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Sotorasib

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on on the 1st day of each period (Days 1 and 4)

Secondary outcomes

  1. Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)

    A TEAE was defined as an adverse event (AE) that started during or after dosing, or started prior to dosing and increased in severity after dosing within each period. Clinically significant laboratory tests, 12-lead electrocardiogram (ECG), or vital sign results as assessed by the Investigator were also recorded as adverse events.

    Time frame: Day 1 to Day 9

  2. Period 3: Cmax of Sotorasib

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on the 1st day of Period 3 (Day 7)

  3. Period 3: AUClast of Sotorasib

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on on the 1st day of Period 3 (Day 7)

  4. Period 3: AUCinf of Sotorasib

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on the 1st day of Period 3 (Day 7)

07

Results

Posted Dec 14, 2023

Participant flow

A total of 146 participants were enrolled with all participants randomized into Treatment Sequences AB and BA, including 14 participants that proceeded to receive Treatment C in the food effect substudy.

Periods 1 & 2
Participant flow — Periods 1 & 2
MilestoneTreatment Sequence ABTreatment Sequence BATreatment Sequence ABCTreatment Sequence BAC
Started737300
Received at least 1 dose737300
Completed727200
Not completed1100
Withdrew: Miscellaneous0100
Withdrew: Withdrawal by subject1000
Period 3 (Food Effect Substudy)
Participant flow — Period 3 (Food Effect Substudy)
MilestoneTreatment Sequence ABTreatment Sequence BATreatment Sequence ABCTreatment Sequence BAC
Started0077
Completed0077
Not completed0000

Outcome measures

PrimaryPeriod 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Sotorasib
Time frame:
Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on the 1st day of each period (Days 1 and 4)
Reported as:
Geometric least squares mean · ng/mL
Period 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Sotorasib
ng/mLTreatment ATreatment B
Period 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Sotorasib4170 ± 75.04340 ± 65.5
Statistical analysis
  • Treatment A vs Treatment B · Ratio of glsm: 0.962 · 90% CI 0.880 to 1.053
PrimaryPeriod 1 and 2: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Sotorasib
Time frame:
Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on the 1st day of each period (Days 1 and 4)
Reported as:
Geometric least squares mean · h*ng/mL
Period 1 and 2: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Sotorasib
h*ng/mLTreatment ATreatment B
Period 1 and 2: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Sotorasib15300 ± 56.215800 ± 54.6
Statistical analysis
  • Treatment A vs Treatment B · Ratio of glsm: 0.968 · 90% CI 0.907 to 1.033
PrimaryPeriod 1 and 2: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Sotorasib
Time frame:
Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on on the 1st day of each period (Days 1 and 4)
Reported as:
Geometric least squares mean · h*ng/mL
Period 1 and 2: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Sotorasib
h*ng/mLTreatment ATreatment B
Period 1 and 2: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Sotorasib15500 ± 54.116100 ± 52.8
Statistical analysis
  • Treatment A vs Treatment B · Ratio of glsm: 0.967 · 90% CI 0.908 to 1.029
SecondaryNumber of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)

A TEAE was defined as an adverse event (AE) that started during or after dosing, or started prior to dosing and increased in severity after dosing within each period. Clinically significant laboratory tests, 12-lead electrocardiogram (ECG), or vital sign results as assessed by the Investigator were also recorded as adverse events.

Time frame:
Day 1 to Day 9
Reported as:
Count of participants · Participants
Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)
ParticipantsTreatment ATreatment BTreatment C
Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)3100
SecondaryPeriod 3: Cmax of Sotorasib
Time frame:
Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on the 1st day of Period 3 (Day 7)
Reported as:
Geometric least squares mean · ng/mL
Period 3: Cmax of Sotorasib
ng/mLTreatment C
Period 3: Cmax of Sotorasib4530 ± 14.2
SecondaryPeriod 3: AUClast of Sotorasib
Time frame:
Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on on the 1st day of Period 3 (Day 7)
Reported as:
Geometric least squares mean · h*ng/mL
Period 3: AUClast of Sotorasib
h*ng/mLTreatment C
Period 3: AUClast of Sotorasib19000 ± 20.3
SecondaryPeriod 3: AUCinf of Sotorasib
Time frame:
Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on the 1st day of Period 3 (Day 7)
Reported as:
Geometric least squares mean · h*ng/mL
Period 3: AUCinf of Sotorasib
h*ng/mLTreatment C
Period 3: AUCinf of Sotorasib19100 ± 20.0

Adverse events

Collected over Day 1 to Day 9. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A0/146 (0%)0/146 (0%)3/146 (2.1%)
Treatment B0/146 (0%)0/146 (0%)10/146 (6.8%)
Treatment C0/14 (0%)0/14 (0%)0/14 (0%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventTreatment ATreatment BTreatment C
HeadacheNervous system disorders0/1463/1460/14
Dermatitis contactSkin and subcutaneous tissue disorders0/1462/1460/14
HaematomaVascular disorders0/1462/1460/14
Abdominal discomfortGastrointestinal disorders0/1461/1460/14
DiarrhoeaGastrointestinal disorders0/1461/1460/14
NauseaGastrointestinal disorders0/1461/1460/14
ToothacheGastrointestinal disorders0/1461/1460/14
VomitingGastrointestinal disorders0/1461/1460/14
Feeling coldGeneral disorders0/1461/1460/14
Back painMusculoskeletal and connective tissue disorders1/1460/1460/14

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Treatment Sequence ABTreatment Sequence BATotal
Mean37.6 ± 11.139.2 ± 10.7438.4 ± 10.91
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence ABTreatment Sequence BATotal
Female61420
Male6759126
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Sequence ABTreatment Sequence BATotal
Hispanic or Latino302959
Not Hispanic or Latino434487
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Treatment Sequence ABTreatment Sequence BATotal
White414485
Black and African American272552
Asian347
American Indian or Alaska Native101
Multiple101
08

Study locations

4 sites
  • Labcorp Clinical Research Unit - Daytona Beach
    Daytona Beach, Florida 32117-5116, United States
  • Miami Research Associates LLC - Main Campus / Late Phase
    South Miami, Florida 33143-5026, United States
  • Labcorp Clinical Research Unit - Dallas
    Dallas, Texas 75247-4989, United States
  • Labcorp Clinical Research Unit - Madison
    Madison, Wisconsin 53704-2526, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Jul 2022, 3 months.

Results were first posted in Dec 2023, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2022
First posted
Apr 14, 2022
StartActual
Mar 21, 2022
Primary completionActual
Jul 17, 2022
CompletionActual
Jul 17, 2022
Results first posted
Dec 14, 2023
Last update
Dec 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05327491
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Apr 14, 2022
Start date
Mar 21, 2022
Primary completion
Jul 17, 2022
Completion
Jul 17, 2022
Results posted
Dec 14, 2023
Last update
Dec 14, 2023

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotorasib

Start the discussion